CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,396 enrolled
Drug / intervention
obstetric outcomes after fresh versus cryopreserved embryo transferbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05362734
NCT05362734N/ACompleted
CompareCT.gov

Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue Trigger

Istituto Clinico Humanitas·observational·Posted May 5, 2022·Updated Jul 7, 2023

In Brief

An observational study evaluating obstetric outcomes after fresh versus cryopreserved embryo transfer for Ovarian Hyperstimulation Syndrome and Pregnancy Related. Completed, enrolled 1,396 participants.

Detailed Summary

Ovarian hyperstimulation syndrome (OHSS) is one of the most dangerous complications of assisted reproduction technology (ART), described in approximatively 3 to 10% of stimulation cycles although an underestimation of the real incidence has been suggested. The use in clinical practice of GnRH antagonist has made it possible to perform the trigger with GnRH analogues, with the advantage of considerably reducing the risk of OHSS.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Hyperstimulation Syndrome, Pregnancy Related
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 5, 2022
Enrollment StartJan 1, 2012
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 4.2 years ago

Interventions

obstetric outcomes after fresh versus cryopreserved embryo transferbehavioral

measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate